▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for M3 in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $80.50.
The current consensus among 3 contributing investment analysts is to buy stock in M3.
M3, Inc. provides medical-related services primarily to physicians and other healthcare professionals through Internet. The company operates m3.com, a members-only Web site for providing information to the healthcare professionals; and MR-kun that delivers medical and drug information online through m3.com. It also provides MDLinx that offers the review of medical articles and theses in English for physicians in the United States; and MEDI:GATE, which provides various medical news and content, and features online discussion boards where doctors can exchange opinions and communicate with one another in South Korea. In addition, the company offers various Internet-based services for pharmaceutical and other medical-related companies, including marketing support services for medical solution providers and healthcare professionals, clinical trial services, clinical trial support services, market research services, and doctor and pharmacist recruiting support services. Further, it provides services for general public, such as the operation of AskDoctors, a Q and A site to consult doctors through the Internet; Ichie Websites comprising Ichie Breast Cancer and Ichie Menopause, which offers insights and solutions related to breast cancer and menopause; and iTicket Plus, a reservation system for clinics through mobile phones and the Internet. The company was formerly known as So-netM3, Inc. and changed its name to M3, Inc. in January 2010. M3, Inc. was founded in 2000 and is headquartered in Tokyo, Japan.